Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma to announce Q4 and FY14 results on May 29, 2014

May 16, 2014, Mumbai: On May 29, 2014, Sun Pharma will announce results for the fourth quarter and the financial year ending March 31, 2014. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (10.00 am IST, May 30, 2014)

The Company will conduct an hour long call at 10.00 am IST on May 30, 2014 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Earnings release	May 29, 2014	www.sunpharma.com
Earnings conference call	10.00 am IST, May 30, 2014	Primary Number : +91 22 3960 0899 Secondary Number : +91 22 6746 8324 Via audio webcast, details of which will be made available on www.sunpharma.com
Replay of conference call	May 30, 2014 to Jun 6, 2014	India: +91 22 3065 1212 ID: 786742 Via audio webcast playback, details of which will be made available on www.sunpharma.com

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2013, overall revenues were at US$2.1 billion, of which US contributed US$1.1 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, diabetology and ophthalmology. The company has strong skills in product

Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685
CIN: L24230GJ1993PLC019050
www.sunpharma.com

development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Nimish Desai
Tel +91 22 6645 5645, Xtn 5717
Tel Direct +91 22 66455717
Mobile +91 98203 30182
E mail nimish.desai@sunpharma.com

Frederick Castro
Tel +91 22 6645 5645, Xtn 5964
Tel Direct +91 22 66455964
Mobile +91 99206 665176
E mail frederick.castro@sunpharma.com